TRANSGENE |
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.24 EUR | -0.32% |
|
-6.20% | -9.49% |
| Apr. 10 | Transgene: presents vaccine results at AACR | CF |
| Mar. 28 | Transgene CFO Steps Down; Successor Assumes Office | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 128.9 | 137.9 | 247.8 | 164.8 | 137.8 | 125.1 | - | - |
| Enterprise Value (EV) 1 | 114.3 | 129.9 | 214.9 | 151.4 | 139.4 | 141.5 | 163.5 | 205.4 |
| P/E ratio | -6.74 x | -7.85 x | -12.1 x | -5.02 x | -6.23 x | -8.89 x | -5.92 x | -2.96 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 9.39 x | 13.9 x | 14.2 x | 15.9 x | 17.4 x | 3.14 x | 2.51 x | 4.2 x |
| EV / Revenue | 8.32 x | 13.1 x | 12.3 x | 14.6 x | 17.6 x | 3.55 x | 3.28 x | 6.89 x |
| EV / EBITDA | -4.63 x | -5.85 x | -10.2 x | -5.37 x | -4.9 x | -12.1 x | -8.65 x | -4.68 x |
| EV / FCF | -4.73 x | -4.39 x | -6.59 x | -6.94 x | -1,408 x | -11.2 x | -8.17 x | -5.17 x |
| FCF Yield | -21.1% | -22.8% | -15.2% | -14.4% | -0.07% | -8.91% | -12.2% | -19.3% |
| Price to Book | 1.96 x | 2.74 x | 3.69 x | 4.38 x | - | -6.91 x | -3.11 x | -1.54 x |
| Nbr of stocks (in thousands) | 83,190 | 83,677 | 97,576 | 99,370 | 100,566 | 100,549 | - | - |
| Reference price 2 | 1.550 | 1.648 | 2.540 | 1.658 | 1.370 | 1.244 | 1.244 | 1.244 |
| Announcement Date | 3/11/20 | 3/10/21 | 3/16/22 | 3/16/23 | 3/27/24 | - | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 13.73 | 9.915 | 17.41 | 10.34 | 7.9 | 39.8 | 49.8 | 29.8 |
| EBITDA 1 | -24.68 | -22.21 | -21 | -28.22 | -28.48 | -11.7 | -18.9 | -43.9 |
| EBIT 1 | -25.45 | -23.99 | -23.52 | -29.9 | -30.05 | -15.7 | -23.9 | -46.9 |
| Operating Margin | -185.35% | -241.99% | -135.1% | -289.1% | -380.34% | -39.45% | -47.99% | -157.38% |
| Earnings before Tax (EBT) | - | -17.23 | -19.54 | -32.8 | - | - | - | - |
| Net income 1 | -18.8 | -17.23 | -19.54 | -32.8 | -22.33 | -13.8 | -21.1 | -41.4 |
| Net margin | -136.93% | -173.79% | -112.19% | -317.13% | -282.63% | -34.67% | -42.37% | -138.93% |
| EPS 2 | -0.2300 | -0.2100 | -0.2100 | -0.3300 | -0.2200 | -0.1400 | -0.2100 | -0.4200 |
| Free Cash Flow 1 | -24.14 | -29.59 | -32.61 | -21.84 | -0.099 | -12.6 | -20 | -39.7 |
| FCF margin | -175.81% | -298.48% | -187.3% | -211.12% | -1.25% | -31.66% | -40.16% | -133.22% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 3/11/20 | 3/10/21 | 3/16/22 | 3/16/23 | 3/27/24 | - | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2022 S1 | 2022 S2 |
|---|---|---|
| Net sales 1 | - | 4.257 |
| EBITDA | - | - |
| EBIT 1 | - | -15.07 |
| Operating Margin | - | -353.98% |
| Earnings before Tax (EBT) 1 | - | -17.52 |
| Net income 1 | -15.28 | -17.52 |
| Net margin | - | -411.67% |
| EPS 2 | -0.1500 | -0.1800 |
| Dividend per Share | - | - |
| Announcement Date | 9/7/22 | 3/16/23 |
1EUR in Million2EUR
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | 1.63 | 16.4 | 38.4 | 80.3 |
| Net Cash position 1 | 14.6 | 7.99 | 32.9 | 13.3 | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | -0.0572 x | -1.402 x | -2.032 x | -1.829 x |
| Free Cash Flow 1 | -24.1 | -29.6 | -32.6 | -21.8 | -0.1 | -12.6 | -20 | -39.7 |
| ROE (net income / shareholders' equity) | -36.7% | -29.7% | -33.1% | -62.5% | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share 2 | 0.7900 | 0.6000 | 0.6900 | 0.3800 | - | -0.1800 | -0.4000 | -0.8100 |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | 1.73 | 0.85 | 0.69 | 1.54 | - | 4.8 | 6 | 3.6 |
| Capex / Sales | 12.6% | 8.59% | 3.94% | 14.84% | - | 12.06% | 12.05% | 12.08% |
| Announcement Date | 3/11/20 | 3/10/21 | 3/16/22 | 3/16/23 | 3/27/24 | - | - | - |
1EUR in Million2EUR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
1.244
EUR
Average target price
3.5
EUR
Spread / Average Target
+181.35%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -9.49% | 134M | |
| -3.00% | 102B | |
| +1.95% | 96.29B | |
| +2.13% | 22.18B | |
| -15.36% | 21.2B | |
| -9.21% | 18.31B | |
| -39.98% | 17.38B | |
| -15.29% | 16.36B | |
| +5.20% | 13.97B | |
| +32.93% | 12.17B |
- Stock Market
- Equities
- TNG Stock
- Financials Transgene
